By Tony Winterburn • 28 January 2021 • 23:17
Novavax Vaccine Effective Against South African Variant In Trials.
Novavax Inc has said its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.
A mid-stage trial of the vaccine in South Africa, where a potent variant of the virus is common, showed 60% effectiveness among people who did not have HIV. Novavax shares rose more than 22% in after-hours trading following the report, which comes on the day the United States reported its first cases of the South African variant.
Novavax said the UK trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for regulatory review in Britain, the European Union and other countries. Some 27% of people in the trial are over age 65.
The study took place as the more highly transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation, the U.S. company announced in a news release. It did not provide the study data.
Thank you for taking the time to read this news article “Novavax Vaccine Effective Against South African Variant In Trials”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you donâ€™t already have one. Review our
Share your story with us by emailing firstname.lastname@example.org, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
Download our media pack in either English or Spanish.